Literature DB >> 1567933

Oxygen saturation during sleep in patients with bronchopulmonary dysplasia.

R Zinman1, P W Blanchard, F Vachon.   

Abstract

We hypothesized that significant sleep desaturation might occur in infants with bronchopulmonary dysplasia whose awake saturations were between 90 and 92%. Supplemental oxygen was continued until the awake saturation on room air was 90% or greater. Sleep saturations were monitored by oximetry sampling for a 3-min period every hour overnight. Significant desaturation was considered to be present if the saturation fell repeatedly below 88%. There were 39 studies performed in room air, and 14 studies in supplemental oxygen. We demonstrated that patients with acceptable awake saturation may desaturate while sleeping. However, only 1 of 25 patients whose saturation in room air was 92% or more repeatedly desaturated during sleep.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567933     DOI: 10.1159/000243533

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  4 in total

1.  Early motor and mental development in very preterm infants with chronic lung disease.

Authors:  M Katz-Salamon; E M Gerner; B Jonsson; H Lagercrantz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

Review 2.  Ventilatory control in infants, children, and adults with bronchopulmonary dysplasia.

Authors:  Melissa L Bates; De-Ann M Pillers; Mari Palta; Emily T Farrell; Marlowe W Eldridge
Journal:  Respir Physiol Neurobiol       Date:  2013-07-22       Impact factor: 1.931

3.  Cognitive development at 5.5 years of children with chronic lung disease of prematurity.

Authors:  B Böhm; M Katz-Salamon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-03       Impact factor: 5.747

4.  Development of peripheral chemoreceptor function in infants with chronic lung disease and initially lacking hyperoxic response.

Authors:  M Katz-Salamon; M Eriksson; B Jónsson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.